There are a handful of upsides to Recursion merging with Exscientia. First, all of Exscientia's pipeline programs will become Recursion's, which gives it that many more opportunities to commercialize ...
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
Recursion Pharmaceuticals (RXRX Quick Quote RXRX - Free Report) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results